Sign in
Not yet recruitingNo phase

Effect of MxA Guidance on Antiviral Treatment in Respiratory Viral Infections

Key facts

Who runs it
Capital Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
618 people, planned
Starts
30 Nov 2026
Expected to end
29 Feb 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Baseline MxA testing
  • Serial MxA testing
  • MxA result feedback and antiviral treatment recommendations
  • Follow-up at Day 30
  • Usual care
Record updated
23 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Age ≥ 18 years old
  • Hospitalized with suspected lower respiratory tract infection (influenza or SARS-CoV-2) , with influenza virus or SARS-CoV-2 infection confirmed by antigen testing or PCR, and a symptom duration of ≤14 days
  • Currently receiving or planned to receive antiviral treatment, with no decision yet made regarding discontinuation of antiviral therapy

Who cannot take part

  • Use vasoactive drugs
  • Receipt of interferon therapy within the past 30 days
  • Contraindications to antiviral therapy
  • Conditions associated with a systemic inflammatory response within the past 30 days, such as stroke, myocardial infarction, or surgery
  • Active tuberculosis
  • Combined rheumatic and autoimmune diseases, such as inflammatory diseases, systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome, etc
  • Tracheal intubation/tracheotomy with mechanical ventilation
  • Immunesuppression
  • Receipt of vaccination within the past 30 days
  • Coinfection with other respiratory viruses or atypical pathogens
  • Inability to obtain adequate samples for study-related testing
  • Coinfection with influenza virus and SARS-CoV-2
  • Expected hospital discharge or death within 48 hours

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the effects of myxovirus resistance protein A (MxA)-guided antiviral treatment on treatment duration and adverse outcomes in adults hospitalized with influenza or COVID-19, compared with usual care.

Read full original descriptionShow less

Participants will be randomly assigned in a 1:1 ratio to the MxA group or the usual care group. In the MxA group, treating physicians will receive blood MxA test results together with treatment recommendations based on those results. In the usual care group, treating physicians will make antiviral treatment decisions without access to MxA results.

The 2 groups in the trial

  • MxA groupTreatment being tested

    Participants will undergo serial MxA testing. Results and MxA-based antiviral treatment recommendations will be provided to treating physicians. Participants discharged before day 30 will receive a telephone follow-up on day 30.

    Treatment: Baseline MxA testing, Serial MxA testing, MxA result feedback and antiviral treatment recommendations, and Follow-up at Day 30

  • Uscal care groupExisting treatment, for comparison

    Participants will undergo baseline MxA testing, but the results will not be disclosed to treating physicians. Antiviral treatment decisions will follow usual care. Participants discharged before day 30 will receive a telephone follow-up on day 30.

    Treatment: Baseline MxA testing, Follow-up at Day 30, and Usual care

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Myxovirus Resistance Protein A Guidance on Antiviral Treatment in Respiratory Viral Infections
Record updated
23 October 2026